Last Updated: 11 Nov 2024
Executive Summary
Benitec Biopharma Ltd ADR (BNTC) is a developing biotechnology company focused on the development of new genetic drugs. The company has a market capitalization of $209.64 million and trades on the NASDAQ exchange. The latest stock price is $10.58.
Company Overview
Benitec Biopharma is headquartered in Hayward, California. The company's mission is to develop new genetic drugs that can treat a variety of diseases. The company's lead drug candidate is BB-001, which is being developed for the treatment of wet age-related macular degeneration (AMD).
Fundamental Analysis
Benitec Biopharma is a pre-revenue company. The company has reported losses in each of the past five years. The company's net loss in 2023 was $22.4 million. The company's cash and cash equivalents were $15.3 million as of June 30, 2023.
The company's financial performance is expected to improve in the coming years. The company is expected to generate revenue from the sale of BB-001 in 2025. The company's revenue is expected to grow to $100 million by 2027.
Technical Analysis
The technical analysis of Benitec Biopharma's stock price shows that the stock is in a downtrend. The stock has been trading below its 50-day and 200-day moving averages for the past six months. The stock's relative strength index (RSI) is also below 50, which indicates that the stock is oversold.
Short Term Outlook
The short-term outlook for Benitec Biopharma's stock is negative. The stock is in a downtrend and is oversold. The stock is likely to continue to decline in the short term.
Long Term Outlook
The long-term outlook for Benitec Biopharma's stock is positive. The company's lead drug candidate, BB-001, has the potential to be a blockbuster drug. The company's financial performance is expected to improve in the coming years. The stock is likely to appreciate in value in the long term.
Analyst Recommendations
The analyst consensus on Benitec Biopharma's stock is "buy." Two analysts have a "strong buy" rating on the stock, and two analysts have a "buy" rating on the stock. The average analyst price target is $24.
